Roxee Medication Guide

Moxidectin

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Tablet Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed May 15, 2026, 10:00 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Illustration placeholder

Moxidectin

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Tablet Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Moxidectin

To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles : Strongylus vulgaris : (adults and L4 / L5 arterial stages), Strongylus edentatus : (adults and tissue stages), Triodontophorus brevicauda : (adults), Triodontophorus serratus : (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum, Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus, Cylicostephanus goldi, Cylicostephanus longibursatus, Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne, Cylicocyclus leptostomum, Cylicocyclus nassatus, Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus, Coronocyclus labiatus, Coronocyclus labratus, Gyalocephalus capitatus, Petrovinema poculatus Small Strongyles : Undifferentiated lumenal larvae Encysted cyathostomes : Late L3 and L4 mucosal cyathostome larvae Ascarids : Parascaris equorum : (adults and L4 larval stages) Pinworms : Oxyuris equi : (adults and L4 larval stages) Hairworms : Trichostrongylus axei : (adults) Large-mouth stomach worms : Habronema muscae : (adults) Horse stomach bots : Gasterophilus intestinalis : (2nd and 3rd instars), Gasterophilus nasalis : (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older. For treatment and control of internal and external parasites: gastrointestinal roundworms ( Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms ( Dictyocaulus viviparus, adult and L4); cattle grubs ( Hypoderma bovis, H. lineatum ); mites ( Chorioptes bovis, Psoroptes ovis ( P. communis var. bovis )); lice ( Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, Bovicola ( Damalinia ) bovis ); and horn flies ( Haematobia irritans ). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment. Species commonly shown: Both, Dog, Excluding Under 8 Weeks Age, Horse, Not For Meat Production.

Generic name

Moxidectin

Brand names

ProHeart™, Quest® Gel, Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle, ProHeart® 6

Manufacturer

Multiple FDA labelers

Species

Both, Dog, Horse, Pony

Dosage forms

Tablet, Gel, Solution, Microspheres

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

ProHeart™ Quest® Gel Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle ProHeart® 6 Cydectin® Cydectin® Oral Drench for Sheep CORAXIS™ ProHeart® 12 Tauramox™ MoxiSolv™ Injection Moxidectin Oral Drench for Sheep AX Pharmaceutical Corp Cydectin Tauramox Moxidectin MoxiSolv Quest ProHeart 12 ProHeart 6

Dosage forms

Tablet Gel Solution Microspheres Liquid (Solution) Sterile suspension Injectable Solution

Indications / Uses

To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles : Strongylus vulgaris : (adults and L4 / L5 arterial stages), Strongylus edentatus : (adults and tissue stages), Triodontophorus brevicauda : (adults), Triodontophorus serratus : (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum , Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus , Cylicostephanus goldi , Cylicostephanus longibursatus , Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne , Cylicocyclus leptostomum , Cylicocyclus nassatus , Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus , Coronocyclus labiatus , Coronocyclus labratus , Gyalocephalus capitatus , Petrovinema poculatus Small Strongyles : Undifferentiated lumenal larvae Encysted cyathostomes : Late L3 and L4 mucosal cyathostome larvae Ascarids : Parascaris equorum : (adults and L4 larval stages) Pinworms : Oxyuris equi : (adults and L4 larval stages) Hairworms : Trichostrongylus axei : (adults) Large-mouth stomach worms : Habronema muscae : (adults) Horse stomach bots : Gasterophilus intestinalis : (2nd and 3rd instars), Gasterophilus nasalis : (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older. For treatment and control of internal and external parasites: gastrointestinal roundworms ( Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms ( Dictyocaulus viviparus , adult and L4); cattle grubs ( Hypoderma bovis , H. lineatum ); mites ( Chorioptes bovis , Psoroptes ovis ( P. communis var. bovis )); lice ( Linognathus vituli , Haematopinus eurysternus , Solenopotes capillatus , Bovicola ( Damalinia ) bovis ); and horn flies ( Haematobia irritans ). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.

Warnings / Contraindications

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

Side Effects

Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Lack of efficacy (endoparasite) - hookworm, Lethargy (see also Central nervous system depression in 'Neurological'), Facial swelling (see also 'Skin'), Diarrhoea.

FAQ

Both, Dog, Excluding Under 8 Weeks Age, Horse, Not For Meat Production, Pony, Beef, Calves, excluding veal calves, Dairy, not breeding age, Dog, Excluding Under 6 Months Of Age, Dairy, excluding female breeding age animals, Sheep, Dog, 1 year of age and older, Beef And Non-Lactating Dairy

Yes. Roxee shows this as prescription-only.

Tablet, Gel, Solution, Microspheres

Related Medications

Related Conditions

Gastrointestinal (additional) Heartworm Disease Intestinal Parasites (Worms) Pica Weight loss

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/807
Last refreshed: Aug 6, 2026, 7:47 p.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For treatment and control of gastrointestinal roundworms: Ostertagia ostertagi (adults, fourth-stage larvae, and inhibited larvae), Haemonchus placei (adults), Trichostrongylus axei (adults and fourth-stage larvae), T. c...

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Use once-a-month in dogs at 8 weeks of age or older
QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only
This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result
Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions
Do not use in sick, debilitated, or underweight animals
Do not use in horses intended for human consumption
A withdrawal period has not been established for this product on preruminating calves
Do not use on calves to be processed for veal
wobbly/unsteady walking (1 reports)
Loss of appetite (1 reports)
Decreased percentage of reticulocytes (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Moxidectin; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-014359

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 26 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-014359

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-014359

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Decreased percentage of reticulocytes (1 reports), Decreased drinking (1 reports), Decreased cholesterol (1 reports)

Body systems represented Signal grouping

Digestive (4), Skin & allergy (1), Neurologic (2), Behavior (2)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (25 reports), Cat (7 reports)

Breed metadata in reports Metadata only

Rottweiler (1), ['Terrier - Bull - American Pit', 'Dog (unknown)'] (1), Retriever - Labrador (1), ['Retriever - Golden', 'Poodle (unspecified)'] (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Moxidectin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Use once-a-month in dogs at 8 weeks of age or older, QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only, This product should not be used in other animal species as severe adverse reactions, including fatal, Extreme caution should be used when administering the product to foals, young and miniature horses,, Do not use in sick, debilitated, or underweight animals

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Moxidectin brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2026-US-014359 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
FOI · document · documents
EA · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Moxidectin Oral Drench for Sheep · official_label
openFDA case USA-USFDACVM-2026-US-014359 · adverse_reaction

Safety & side effects

Side effects to monitor:

Use once-a-month in dogs at 8 weeks of age or older
QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only
This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result
Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions
Do not use in sick, debilitated, or underweight animals

Most reported reactions:

Unsteady walking (ataxia) (1 reports)
Loss of appetite (1 reports)
Decreased percentage of reticulocytes (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

1 year of age and older, Beef, Beef And Non-Lactating Dairy, Calves, Dairy, Dog, Horse, Pony, Sheep

Indication / use

For treatment and control of gastrointestinal roundworms: Ostertagia ostertagi (adults, fourth-stage larvae, and inhibited larvae), Haemonchus placei (adults), Trichostrongylus ax…

Form / route / dose

Form: Gel, Injectable Solution, Liquid (Solution), Microspheres, Solution, Sterile suspension, Tablet
Route: Oral, Subcutaneous, Topical, Transdermal
Confirm product label and patient-specific plan.

Warnings

High: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a lic…

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

141-220 Official label / PI
141-220 Official label / PI
Final version PROHEART12 N141519C0004.pdf Official label / PI

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA labelers

Form: Gel, Injectable Solution, Liquid (Solution), Microspheres, Solution, Sterile suspension

Identifiers:

ANADA: 200615 ANADA: 200638 ANADA: 200700 ANADA: 200701 ANADA: 200714 ANADA: 200716 ANADA: 200718 ANADA: 200721 ANADA: 200746 ANADA: 200788 ANADA: 200811 ANADA: 200818 ANADA: 200852 NADA: 141051 NADA: 141087 NADA: 141099 NADA: 141189 NADA: 141216 NADA: 141220 NADA: 141247

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141220 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141519 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

High: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Lack of efficacy (endoparasite) - heartworm (14) Medication error NOS (12) Lack of efficacy (endoparasite) - hookworm (9) Lethargy (see also Central nervous system depression in Neurological) (8) Other (44) Effectiveness (26) Digestive (18) Neurologic (16)

Showing up to 50 matching reports. Narrow filters to inspect the remaining reports.

USA-USFDACVM-2026-US-014448

Received 2026-03-27 · MSK · MSK

Serious

Species: Dog
Breed: Rottweiler
Size / weight: 50-99 lb (39.372 Kilogram)
Age: 8+ years (8 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartwormWeight loss
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014408

Received 2026-03-27 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier - Bull - American Pit', 'Dog (unknown)']
Size / weight: 50-99 lb (24.494 Kilogram)
Age: 1-3 years (3 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - hookwormMedication error NOS
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014406

Received 2026-03-27 · MSK · MSK

Serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (38.646 Kilogram)
Age: 8+ years (11 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartwormMedication error NOS
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014405

Received 2026-03-27 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Golden', 'Poodle (unspecified)']
Size / weight: 25-49 lb (12.61 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - tapewormMedication error NOS
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014402

Received 2026-03-27 · MSK · MSK

Serious

Species: Dog
Breed: ['Shepherd Dog - German', 'Retriever - Labrador']
Size / weight: 50-99 lb (39.009 Kilogram)
Age: 4-7 years (5 Year)
Sex: Female Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartwormIntentional misuseInappropriate schedule of drug administration
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014387

Received 2026-03-27 · MSK · MSK

Serious

Species: Dog
Breed: Crossbred Canine/dog
Size / weight: 50-99 lb (25.492 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - hookworm
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2026-US-014504

Received 2026-03-26 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (5.117 Kilogram)
Age: Under 1 year (11 Month)
Sex: Male Neutered
Region: USA
Reactions: Suckling disorder NOSLickingSkin scabPeripheral vascular disorderPinnal erythemaCrustExpired drug administered
Body systems: Other
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-014403

Received 2026-03-26 · MSK · MSK

Serious

Species: Dog
Breed: Terrier - Yorkshire
Size / weight: 10-24 lb (6.622 Kilogram)
Age: 1-3 years (3 Year)
Sex: Male Intact
Region: USA
Reactions: Emesis (multiple)Lethargy (see also Central nervous system depression in Neurological)Loose bowel
Body systems: DigestiveNeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014071

Received 2026-03-26 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund - Miniature
Size / weight: 10-24 lb (5.543 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Intact
Region: USA
Reactions: Facial swelling (see also Skin)
Body systems: Skin & allergy
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-014457

Received 2026-03-25 · MSK · MSK

Non-serious

Species: Dog
Breed: Shepherd Dog - Belgian Malinois
Size / weight: 50-99 lb (24.766 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Unknown
Region: USA
Reactions: Skin lumpLethargy (see also Central nervous system depression in Neurological)Immediate pain upon injectionAbnormal cytologyMedication error NOS
Body systems: OtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-014377

Received 2026-03-25 · MSK · MSK

Serious

Species: Dog
Breed: ['Siberian Husky', 'Terrier - Bull - American Pit']
Size / weight: 50-99 lb (29.483 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: Elevated aspartate aminotransferase (AST)Emesis (multiple)Bloody diarrhoeaLethargy (see also Central nervous system depression in Neurological)HypothermiaBlood in vomitAbnormal ultrasound findingElevated total bilirubinHypokalaemiaNeutrophiliaAnaphylaxisElevated liver enzymes NOS
Body systems: OtherDigestiveNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-014067

Received 2026-03-25 · MSK · MSK

Serious

Species: Dog
Breed: Crossbred Canine/dog
Size / weight: 25-49 lb (18.144 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Unknown
Region: USA
Reactions: Seizure NOSShakingIncreased salivationChattering of teeth
Body systems: NeurologicOtherDigestive
Outcomes: Ongoing

USA-USFDACVM-2026-US-013741

Received 2026-03-24 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Labrador', 'Poodle (unspecified)']
Size / weight: 10-24 lb (6.985 Kilogram)
Age: Under 1 year (6 Month)
Sex: Male Intact
Region: USA
Reactions: Emesis (multiple)Generalised itchingAnaphylaxis
Body systems: DigestiveSkin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-013479

Received 2026-03-24 · MSK · MSK

Serious

Species: Dog
Breed: Terrier - Bull - Staffordshire
Size / weight: 50-99 lb (33.611 Kilogram)
Age: 1-3 years (2 Year)
Sex: Female Unknown
Region: USA
Reactions: Facial swelling (see also Skin)Hypersensitivity reactionEmesis (multiple)Bloody diarrhoeaAtaxiaElevated total bilirubinElevated alanine aminotransferase (ALT)Elevated blood urea nitrogen (BUN)Lethargy (see also Central nervous system depression in Neurological)Intentional misuse
Body systems: Skin & allergyOtherDigestiveNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-013476

Received 2026-03-24 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Labrador', 'Shepherd (unspecified)']
Size / weight: 50-99 lb (34.019 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Neutered
Region: USA
Reactions: Seizure NOSDrunken gaitShakingUnable to walkFear/fearful
Body systems: NeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-013422

Received 2026-03-23 · MSK · MSK

Serious

Species: Dog
Breed: ['Chihuahua', 'Dog (unknown)']
Size / weight: 10-24 lb (10.795 Kilogram)
Age: 1-3 years (3 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartwormIntentional misuse
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-013212

Received 2026-03-23 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund - Miniature
Size / weight: 10-24 lb (5.897 Kilogram)
Age: 8+ years (14 Year)
Sex: Male Neutered
Region: USA
Reactions: Seizure NOSObtundedTwitchingRestlessnessWalking difficultyProprioception deficitDeath by euthanasia
Body systems: NeurologicOtherSkin & allergy
Outcomes: Euthanized

USA-USFDACVM-2026-US-013203

Received 2026-03-21 · MSK · MSK

Serious

Species: Dog
Breed: Crossbred Canine/dog
Size / weight: 50-99 lb (31.389 Kilogram)
Age: 8+ years (8 Year)
Sex: Female Unknown
Region: USA
Reactions: VomitingMedication error NOSDrug dose administration interval too long
Body systems: DigestiveOther
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-013496

Received 2026-03-20 · MSK · MSK

Serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (33.929 Kilogram)
Age: 8+ years (8 Year)
Sex: Male Neutered
Region: USA
Reactions: Seizure NOSElevated liver enzymes NOS
Body systems: NeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-013474

Received 2026-03-20 · MSK · MSK

Serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (23.587 Kilogram)
Age: 1-3 years (3 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartwormMedication error NOS
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-012880

Received 2026-03-19 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Labrador', 'Dog (unknown)']
Size / weight: 50-99 lb (28.576 Kilogram)
Age: 4-7 years (4 Year)
Sex: Male Neutered
Region: USA
Reactions: Emesis (multiple)DiarrhoeaLethargy (see also Central nervous system depression in Neurological)Difficulty standingDehydration
Body systems: DigestiveNeurologicOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-013254

Received 2026-03-18 · MSK · MSK

Non-serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (37.82 Kilogram)
Age: 1-3 years (1 Year)
Sex: Male Intact
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartworm
Body systems: Effectiveness
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-012896

Received 2026-03-18 · MSK · MSK

Serious

Species: Dog
Breed: ['Chihuahua', 'Dachshund (unspecified)']
Size / weight: 10-24 lb (5.761 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartwormMedication error NOSIntentional misuseLack of efficacy (endoparasite) - roundworm NOS
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-014359

Received 2026-03-16 · MSK · MSK

Serious

Species: Dog
Breed: ['Siberian Husky', 'Shepherd Dog - German']
Size / weight: 50-99 lb (41.277 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Intact
Region: USA
Reactions: Other abnormal test result NOSLack of efficacy (endoparasite) - heartwormLethargy (see also Central nervous system depression in Neurological)Death by euthanasiaBlood in urineCloudy eye (for Miosis, Mydriasis, Anisocoria, Nystagmus - see Neurological)CoughSwelling NOSCorneal opacityUrine abnormalities NOSWeaknessIncreased lung soundsHaemolytic anaemiaNot eatingAbnormal breathingWalking difficultyDecreased red blood cell countDecreased percentage of reticulocytes
Body systems: OtherEffectivenessNeurologicSkin & allergy
Outcomes: Euthanized

USA-USFDACVM-2026-US-012837

Received 2026-03-16 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Golden', 'Poodle (unspecified)']
Size / weight: 25-49 lb (16.783 Kilogram)
Age: 1-3 years (3 Year)
Sex: Male Neutered
Region: USA
Reactions: VomitingSwelling around eye (see also Immune system disorders)WhiningUncomfortableFeverInjected scleraPinnal erythemaHypersensitivity reaction
Body systems: DigestiveSkin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-012647

Received 2026-03-16 · MSK · MSK

Non-serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (22.861 Kilogram)
Age: 8+ years (14 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - hookwormUrinary tract infection
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-012730

Received 2026-03-13 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund (unspecified)
Size / weight: 10-24 lb (7.62 Kilogram)
Age: 8+ years (12 Year)
Sex: Female Unknown
Region: USA
Reactions: EmesisLack of efficacy - NOS
Body systems: DigestiveEffectiveness
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-010460

Received 2026-03-05 · MSK · MSK

Serious

Species: Dog
Breed: Terrier - Bull - American Pit
Size / weight: 50-99 lb (29.257 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Neutered
Region: USA
Reactions: Facial swelling (see also Skin)Hives (see also Skin)Administration error NOSHypersensitivity reaction
Body systems: Skin & allergyOther
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-012550

Received 2026-02-21 · MSK · MSK

Serious

Species: Dog
Breed: ['Crossbred Canine/dog', 'Catahoula Leopard Dog']
Size / weight: 50-99 lb (25.129 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: DroolingJaw disorderSeizure NOSLateral recumbencyStiffness NOSConvulsionDisorientationWobblinessElevated total bilirubinStraining to defecateAbnormal stool colourationPost ictal state
Body systems: DigestiveOtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2025-US-077538

Received 2025-12-30 · MSK · MSK

Non-serious

Species: Dog
Breed: Pekingese
Size / weight: 10-24 lb (5.987 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: Facial swelling (see also Skin)Hypersensitivity reaction
Body systems: Skin & allergyOther
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-075460

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: Deutsche Dogge, Great Dane
Size / weight: 100+ lb (57.606 Kilogram)
Age: 1-3 years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: Hives (see also Skin)Facial swelling (see also Skin)Reddening of the skinHypersensitivity reactionTachycardia
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-075429

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: ['Sheepdog (unspecified)', 'Dog (unknown)']
Size / weight: 25-49 lb (16.692 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartworm
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2025-US-075414

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: ['Chihuahua', 'Dog (unknown)']
Size / weight: Under 10 lb (4.246 Kilogram)
Age: 8+ years (12 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - whipwormMedication error NOS
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-075401

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: Coonhound (unspecified)
Size / weight: 25-49 lb (21.319 Kilogram)
Age: 1-3 years (3 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - hookworm
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2025-US-075384

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: Terrier - Yorkshire
Size / weight: 10-24 lb (6.622 Kilogram)
Age: 8+ years (8 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - hookworm
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2025-US-075282

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier (unspecified)', 'Dog (unknown)']
Size / weight: 25-49 lb (13.063 Kilogram)
Age: 1-3 years (3 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartworm
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2025-US-075277

Received 2025-12-29 · MSK · MSK

Serious

Species: Dog
Breed: Shih Tzu
Size / weight: 10-24 lb (5.244 Kilogram)
Age: Under 1 year (1 Month)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - hookwormIntentional misuse
Body systems: EffectivenessOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-075443

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund (unspecified)
Size / weight: 10-24 lb (7.348 Kilogram)
Age: 1-3 years (1.5 Year)
Sex: Male Neutered
Region: USA
Reactions: Pale mucous membraneFacial swelling (see also Skin)Periorbital oedemaHives (see also Skin)Hypersensitivity NOS
Body systems: OtherSkin & allergy
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-075392

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Golden', 'Poodle (unspecified)']
Size / weight: 50-99 lb (22.68 Kilogram)
Age: 4-7 years (4 Year)
Sex: Male Neutered
Region: USA
Reactions: AnorexiaWeight lossDiscoloured urineElevated serum alkaline phosphatase (ALP)Elevated total bilirubinHypoproteinaemiaAnaemia NOSThrombocytopeniaNeutropeniaLethargy (see also Central nervous system depression in Neurological)Tachypnoea
Body systems: DigestiveOtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2025-US-075387

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: ['Shepherd Dog - Australian', 'Poodle (unspecified)']
Size / weight: 50-99 lb (24.131 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: PolyuriaSoft stoolVomiting
Body systems: OtherDigestive
Outcomes: Ongoing

USA-USFDACVM-2025-US-075359

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: ['Spaniel - King Charles Cavalier', 'Poodle (unspecified)']
Size / weight: 10-24 lb (7.439 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: VomitingBloody stool
Body systems: DigestiveOther
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-075348

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (29.03 Kilogram)
Age: 8+ years (1 Year)
Sex: Female Neutered
Region: USA
Reactions: Elevated symmetrical dimethylarginine (SDMA)Elevated creatinineUrinary tract infection
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2025-US-075342

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: Poodle - Standard
Size / weight: 25-49 lb (19.142 Kilogram)
Age: 8+ years (9 Year)
Sex: Female Unknown
Region: USA
Reactions: PruritusElevated alanine aminotransferase (ALT)Elevated serum alkaline phosphatase (ALP)NeutrophiliaEosinopenia
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-075154

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier - Jack Russell', 'Dog (unknown)']
Size / weight: 10-24 lb (8.437 Kilogram)
Age: 1-3 years (3.5 Year)
Sex: Female Unknown
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartworm
Body systems: Effectiveness
Outcomes: Ongoing

USA-USFDACVM-2025-US-074261

Received 2025-12-19 · MSK · MSK

Serious

Species: Dog
Breed: ['Shepherd Dog - Australian', 'Poodle (unspecified)']
Size / weight: 25-49 lb (19.777 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Unknown
Region: USA
Reactions: VomitingDiarrhoea
Body systems: Digestive
Outcomes: Ongoing

USA-USFDACVM-2025-US-074194

Received 2025-12-19 · MSK · MSK

Serious

Species: Dog
Breed: Bulldog - French
Size / weight: 25-49 lb (12.428 Kilogram)
Age: 8+ years (8 Year)
Sex: Male Neutered
Region: USA
Reactions: Decreased appetiteDecreased drinkingLethargy (see also Central nervous system depression in Neurological)PantingTense musclesSeizure NOSInappropriate defecationInappropriate urinationUnable to walkProprioception deficitGeneralised weaknessLamenessLimb non-weight bearingAbnormal radiograph findingMedication error NOS
Body systems: DigestiveOtherNeurologic
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-074384

Received 2025-12-18 · MSK · MSK

Serious

Species: Dog
Breed: Shepherd Dog - German
Size / weight: 50-99 lb (38.555 Kilogram)
Age: 8+ years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: Limb weaknessHind limb ataxiaProprioception deficitDifficulty standingHind limb paresisLoose stoolNot himself/herselfElevated serum alkaline phosphatase (ALP)Elevated creatinineColitisSpondylosisAbnormal radiograph finding
Body systems: OtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2025-US-074361

Received 2025-12-18 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier - Jack Russell', 'Terrier - Bull - American Pit']
Size / weight: 25-49 lb (17.236 Kilogram)
Age: 1-3 years (1 Year)
Sex: Female Unknown
Region: USA
Reactions: Emesis (multiple)Hives (see also Skin)Reddening of the skinSkin irritationUrine leakageHypersensitivity reaction
Body systems: DigestiveSkin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-074282

Received 2025-12-18 · MSK · MSK

Serious

Species: Dog
Breed: Shih Tzu
Size / weight: Under 10 lb (4.445 Kilogram)
Age: 1-3 years (1 Year)
Sex: Female Unknown
Region: USA
Reactions: DiarrhoeaVomitingBloody diarrhoeaElevated haematocritLymphocytosis
Body systems: DigestiveOther
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-073848

Received 2025-12-18 · MSK · MSK

Non-serious

Species: Dog
Breed: ['Cattle Dog (unspecified)', 'Crossbred Canine/dog']
Size / weight: 25-49 lb (14.88 Kilogram)
Age: 1-3 years (3.5 Year)
Sex: Female Neutered
Region: USA
Reactions: Lack of efficacy (endoparasite) - heartworm
Body systems: Effectiveness
Outcomes: Outcome Unknown

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (4) · Loss of appetite, Decreased appetite, Bloody diarrhoea Skin & allergy (1) · Chewing - pruritus Neurologic (2) · Unsteady walking (ataxia), Convulsion Behavior (2) · Biting -aggression, Behavioral disorder (unspecified) Other (23) · Decreased percentage of reticulocytes, Decreased drinking, Decreased cholesterol

Most Reported Reactions

Body system	Cases	Species	Serious cases
Neurologic	1	Dog	1
Digestive	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Digestive	1	Dog	1
Other	1	Dog	1
Other	1	Cat	1

Species coverage: Dog (25) Cat (7)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Neurologic	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Neurologic	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Skin & allergy	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Behavior	Cat	Non-serious	-	1
Behavior	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2026-US-014359

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

141-220 Official label / PI · EA 141-220 Official label / PI · FONSI Final version PROHEART12 N141519C0004.pdf Official label / PI · Labeling

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

SPL

Open original

Cydectin®

SPL · SPL

Open original

FDA Structured Product Label

Cydectin®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Elanco US Inc.
NADA: 141-220
Status: OTC
Form: Liquid (Solution)
Route: Subcutaneous
Species: Beef • Dairy

Composition / specifications

Contains 10 mg moxidectin/mL

Cattle (Beef and Non-Lactating Dairy)

Indication

For treatment and control of gastrointestinal roundworms: Ostertagia ostertagi (adults, fourth-stage larvae, and inhibited larvae), Haemonchus placei (adults), Trichostrongylus axei (adults and fourth-stage larvae), T. colubriformis (adults and fourth-stage larvae), Cooperia oncophora (adults), C. pectinate (adults), C. punctate (adults and fourth-stage larvae), C. spatulata (adults), C. surnabad (adults and fourth-stage larvae), Nematodirus helvetianus (adults), Oesophagostomum radiatum (adults and fourth-stage larvae), Trichuris spp. (adults); lungworms: Dictyocaulus viviparous (adults and fourth-stage larvae); grubs: Hypoderma bovis and H. lineatum; mites: Psoroptes ovis (P. communis var. bovis); lice: Linognathus vituli and Solenopotes capillatus; for protection of cattle from reinfection with D. viviparous and O. radiatum for 42 days after treatment, with H. placei for 35 days after treatment, and with O. ostertagi and T. axei for 14 days after treatment.

Dosage

0.2 mg/kilogram body weight (0.2 mg/2.2 pound) as a single subcutaneous injection.

Limitations

Do not slaughter cattle within 21 days of treatment. Because a withholding time for milk has not been established, do not use in female dairy cattle of breeding age. A withdrawal period has not been established for preruminating calves. Do not use in calves to be processed for veal.

ProHeart® 12

SPL · SPL

Open original

FDA Structured Product Label

ProHeart® 12

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-519
Status: RX
Form: Sterile suspension
Route: Subcutaneous
Species: 1 year of age and older

Composition / specifications

Each mL of constituted suspension contains 10 mg moxidectin

Dogs 1 year of age and older

Indication

For use in dogs 12 months of age and older for the prevention of heartworm disease caused by Dirofilaria immitis for 12 months. For the treatment of existing larval and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections.

Dosage

The recommended subcutaneous dose is 0.05 mL of the constituted suspension/kg body weight (0.023 mL/lb). This amount of suspension will provide 0.5 mg moxidectin/kg body weight (0.23 mg/lb). To ensure accurate dosing, calculate each dose based on the dog’s weight at the time of treatment.

Moxidectin Oral Drench for Sheep

SPL · SPL

Open original

FDA Structured Product Label

Moxidectin Oral Drench for Sheep

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: First Priority, Inc.
ANADA: 200-852
Status: OTC
Form: Solution
Route: Oral

Composition / specifications

1 mg moxidectin/mL

Sheep

Indication

Moxidectin Oral Drench for Sheep, when administered at the recommended dose level of 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight, is effective in the treatment and control of adult and larval (L4) stages of the following internal parasites of sheep:
Parasites
Haemonchus contortus - Adult and L4
Teladorsagia circumcincta - Adult and L4
Teladorsagia trifurcata - Adult and L4
Trichostrongylus axei - Adult and L4
Trichostrongylus colubriformis - Adult and L4
Trichostrongylus vitrinus - Adult and L4
Cooperia curticei - Adult and L4
Cooperia oncophora - Adult and L4
Oesophagostomum columbianum - Adult and L4
Oesophagostomum venulosum - Adult and L4
Nematodirus battus - Adult and L4
Nematodirus filicollis - Adult and L4
Nematodirus spathiger - Adult and L4

Dosage

The recommended rate of administration for Moxidectin Oral Drench for Sheep is 1 mL per 11 lb (1 mL per 5 kg) body weight into the mouth of sheep, using any standard drenching equipment.

MoxiSolv™ Injection

SPL · SPL

Open original

FDA Structured Product Label

MoxiSolv™ Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
ANADA: 200-788
Status: OTC
Form: Injectable Solution
Route: Subcutaneous
Species: Beef And Non-Lactating Dairy

Composition / specifications

10 mg moxidectin/mL

Beef and nonlactating dairy cattle

Indication

For the treatment and control of the following internal and external parasites of cattle:

Gastrointestinal Roundworms
Ostertagia ostertagi - Adults and L4 (including inhibited Larvae)
Haemonchus placei - Adults
Trichostrongylus axei - Adults and L4
Trichostrongylus colubriformis - Adults and L4
Cooperia oncophora - Adults
Cooperia pectinata - Adults
Cooperia punctata - Adults and L4
Cooperia spatulata - Adults
Cooperia surnabada - Adults and L4
Nematodirus helvetianus - Adults
Oesophagostomum radiatum - Adults and L4
Trichuris spp. - Adults

Lungworms
Dictyocaulus viviparus - Adults and L4

Cattle Grubs
Hypoderma bovis
Hypoderma lineatum

Mites
Psoroptes ovis
(Psoroptes communis var. bovis)

Lice
Linognathus vituli
Solenopotes capillatus

Persistent Activity
Moxidectin injectable has been proven to effectively protect cattle from reinfection with Dictyocaulus viviparus and Oesophagostomum radiatum for 42 days after treatment, Haemonchus placei for 35 days after treatment, and Ostertagia ostertagi and Trichostrongylus axei for 14 days after treatment.

Dosage

1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.

Quest® Gel

SPL · SPL

Open original

FDA Structured Product Label

Quest® Gel

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-087
Status: OTC
Form: Gel
Route: Oral
Species: Horse • Pony

Composition / specifications

The gel contains 2 percent moxidectin (20 milligrams per milliliter).

Horses and Ponies (6 Months of Age and Older)

Indication

For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles: Strongylus vulgaris: (adults and L4 / L5 arterial stages), Strongylus edentatus: (adults and tissue stages), Triodontophorus brevicauda: (adults), Triodontophorus serratus: (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum, Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus, Cylicostephanus goldi, Cylicostephanus longibursatus, Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne, Cylicocyclus leptostomum, Cylicocyclus nassatus, Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus, Coronocyclus labiatus, Coronocyclus labratus, Gyalocephalus capitatus, Petrovinema poculatus Small Strongyles: Undifferentiated lumenal larvae Encysted cyathostomes: Late L3 and L4 mucosal cyathostome larvae Ascarids: Parascaris equorum: (adults and L4 larval stages) Pinworms: Oxyuris equi: (adults and L4 larval stages) Hairworms: Trichostrongylus axei: (adults) Large-mouth stomach worms: Habronema muscae: (adults) Horse stomach bots: Gasterophilus intestinalis: (2nd and 3rd instars), Gasterophilus nasalis: (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older.

Dosage

0.4 mg moxidectin/ kg body weight

Limitations

QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption.

Tauramox™

SPL · SPL

Open original

FDA Structured Product Label

Tauramox™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Norbrook Laboratories, Ltd.
ANADA: 200-746
Status: OTC
Form: Injectable Solution
Route: Subcutaneous
Species: Beef And Non-Lactating Dairy

Composition / specifications

10 mg moxidectin/mL

Beef and nonlactating dairy cattle

Indication

For the treatment and control of the following internal and external parasites of cattle:

Gastrointestinal Roundworms
Ostertagia ostertagi – Adults and L4 (including inhibited Larvae)
Haemonchus placei – Adults
Trichostrongylus axei – Adults and L4
Trichostrongylus colubriformis – Adults and L4
Cooperia oncophora – Adults
Cooperia pectinata – Adults
Cooperia punctata – Adults and L4
Cooperia spatulata – Adults
Cooperia surnabada – Adults and L4
Nematodirus helvetianus – Adults
Oesophagostomum radiatum – Adults and L4
Trichuris spp. – Adults
Lungworms
Dictyocaulus viviparus – Adults and L4
Cattle Grubs
Hypoderma bovis
Hypoderma lineatum
Mites
Psoroptes ovis (Psoroptes communis var. bovis)
Lice
Linognathus vituli
Solenopotes capillatus
Persistent Activity: Moxidectin Injectable has been proven to effectively protect cattle from reinfection with Dictyocaulus viviparus and Oesophagostomum radiatum for 42 days after treatment, Haemonchus placei for 35 days after treatment, and Ostertagia ostertagi and Trichostrongylus axei for 14 days after treatment.

Dosage

Administer by subcutaneous injection 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.

Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle

SPL · SPL

Open original

FDA Structured Product Label

Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Elanco US Inc.
NADA: 141-099
Status: OTC
Form: Solution
Route: Transdermal
Species: Beef • Calves • Dairy

Composition / specifications

Each milliliter contains 5 milligrams of moxidectin (0.5 percent solution).

Beef and Dairy Cattle

Indication

For treatment and control of internal and external parasites: gastrointestinal roundworms (Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms (Dictyocaulus viviparus, adult and L4); cattle grubs (Hypoderma bovis, H. lineatum); mites (Chorioptes bovis, Psoroptes ovis (P. communis var. bovis)); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, Bovicola(Damalinia) bovis); and horn flies (Haematobia irritans). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.

Dosage

The recommended rate of administration is 1 mL for each 22 lb (10 kg) of body weight which provides 5 mg moxidectin for each 22 lb (10 kg) of body weight.

Limitations

A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

ProHeart® 6

SPL · SPL

Open original

FDA Structured Product Label

ProHeart® 6

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-189
Status: RX
Form: Microspheres
Route: Subcutaneous
Species: Dog

Composition / specifications

The drug product consists of two separate vials. One contains 10 percent moxidectin microspheres, and the other contains a vehicle for constitution of the moxidectin microspheres. Each milliliter of constituted, sustained-release suspension contains 3.4 milligrams (mg) of moxidectin.

Dogs

Indication

For treatment of existing larval and adult hookworm (Ancylostoma caninum and Unicinaria stenocephala) infections.

Dosage

0.05 mL of the constituted suspension/kg body weight (0.0227 mL/lb). This amount of suspension will provide 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.

Limitations

Do not administer ProHeart 6 to dogs who are sick, debilitated, underweight or who have a history of weight loss. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. To ensure accurate dosing, calculate each dose based on the dog’s weight at the time of treatment. Do not overdose growing puppies in anticipation of their expected adult weight. No more than 3 mL should be administered in a single site. ProHeart 6 should not be used more frequently than every 6 months. The safety and eff ectiveness of ProHeart 6 has not been evaluated in dogs less than 6 months of age. Caution should be used when administering ProHeart 6 to heartworm positive dogs.

Indication

For prevention of heartworm disease caused by Dirofilaria immitis.

Dosage

0.05 mL of the constituted suspension/kg body weight (0.0227 mL/lb). This amount of suspension will provide 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.

Limitations

Cydectin® Oral Drench for Sheep

SPL · SPL

Open original

FDA Structured Product Label

Cydectin® Oral Drench for Sheep

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Elanco US Inc.
NADA: 141-247
Status: OTC
Form: Liquid (Solution)
Route: Oral
Species: Sheep

Composition / specifications

Each milliliter (mL) of solution contains 1 milligram (mg) moxidectin.

Sheep

Indication

For the treatment and control of the adult and L4 larval stages of Haemonchus contortus, Teladorsagia circumcincta, T. trifurcate, Trichostrongylus axei, T. colubriformis, T. vitrines, Cooperia curticei, C. oncophora, Oesophagostomum columbianum, O. venulosum, Nematodirus battus, N. filicollis, and N. spathiger.

Dosage

Administer 1 mL per 11 pounds body weight (1 mL per 5 kilograms) by mouth.

Limitations

CYDECTIN Oral Drench for Sheep has been formulated specifically for oral use in sheep and should not be given by any other route of administration. Do not use in sick, debilitated, or underweight animals. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.

ProHeart™

SPL · SPL

Open original

FDA Structured Product Label

ProHeart™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-051
Status: RX
Form: Tablet
Route: Oral
Species: Dog

Composition / specifications

Each tablet contains 30, 68, or 136 micrograms of moxidectin.

Dogs

Indication

To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease.

Dosage

3 micrograms per kilogram (1.36 micrograms per pound) of body weight, once a month.

Limitations

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

CORAXIS™

SPL · SPL

Open original

FDA Structured Product Label

CORAXIS™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Elanco US Inc.
NADA: 141-417
Status: RX
Form: Solution
Route: Topical
Species: Dog

Composition / specifications

2.5% moxidectin

Dogs (Dogs and Puppies At Least 7 Weeks of Age)

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/753 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/752 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadEA/147 · document · EA
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFonsi/150 · document · FONSI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/503/Cydectin%C2%AE · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/7307 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/893 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/894 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/7349/ProHeart%C2%AE%2012 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/18369 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed May 15, 2026, 10:00 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: AX Pharmaceutical Corp Cydectin MoxiSolv Moxidectin ProHeart 12 ProHeart 6 Quest Tauramox

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: 1 year of age and older, Beef, Beef And Non-Lactating Dairy, Calves, Dairy, Dog, Horse, Pony, Sheep

Rx/OTC: OTC, RX

Form/route: Gel, Injectable Solution, Liquid (Solution), Microspheres, Solution, Sterile suspension, Tablet • Oral, Subcutaneous, Topical, Transdermal

Applications: NADA 141-220 • NADA 141-519 • ANADA 200-852 • ANADA 200-788 • NADA 141-087 • ANADA 200-746 • NADA 141-099 • NADA 141-189 • NADA 141-247 • NADA 141-051 • NADA 141-417

NDC: Packages 20076-1235-2 20076-1235-3 30798-314-17 54771-0254-1 54771-0255-1 54771-0256-1 • Products 20076 30798 54771 55529 58198 61133

Documents: 28 (FOI: 20) • SPL: 11 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 139 • Cat 7 • View

Case summaries: 60 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Gastrointestinal (additional) Heartworm Disease Intestinal Parasites (Worms) Pica Weight loss

Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: B74.8 ICD10_CM: B82.9 ICD10_CM: B86 ICD10_CM: B88.1

Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal. (Contraindication, High)

Top reaction signals

Unsteady walking (ataxia) (1) Loss of appetite (1) Decreased percentage of reticulocytes (1) Decreased drinking (1) Decreased cholesterol (1) Decreased appetite (1) Death by euthanasia (1) Death (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
0010-4260-01	0010	-
0010-4260-02	0010	-
0010-4260-03	0010	-
0010-4261-01	0010	-
0010-4261-02	0010	-
0010-4261-03	0010	-
0010-4262-01	0010	-
0010-4262-02	0010	-
0010-4262-03	0010	-
0010-4263-01	0010	-
0010-4263-02	0010	-
0010-4263-03	0010	-
0010-4264-01	0010	-
0010-4264-02	0010	-
0010-4264-03	0010	-
0061-5996-01	0061	-
0061-5997-01	0061	-
0061-5998-01	0061	-
17030-023-01	17030	-
17030-023-03	17030	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Moxidectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
ProHeart 12 SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
ProHeart 6 SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Quest SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
MoxiSolv SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Cydectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Tauramox SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Cydectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
MoxiSolv SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Moxidectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Cydectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Cydectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Cydectin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
ucm118028.pdf • FOI summary • Official • June 10, 2026
FDA FOI summary for application 141220
ucm118029.pdf • FOI summary • Official • June 10, 2026
FDA FOI summary for application 141220
Final version PROHEART12 N141519C0004.pdf • Official label • Official • May 14, 2026
FDA official labeling for application 141519
Final version PROHEART12 N141519C0004.pdf • Official label • Official • May 14, 2026
FDA official labeling for application 141519
FOI Summary oN 141-519 Approved July 2, 2019.pdf • FOI summary • Official • May 14, 2026
FDA FOI summary for application 141519
FOI Summary oA 200-852 Approved April 29, 2026.pdf • FOI summary • Official • April 30, 2026
FDA FOI summary for application 200852
FOI Summary oN 141-581 Approved October 7, 2024.pdf • FOI summary • Official • March 9, 2026
FDA FOI summary for application 141581
FOI Summary sN 141-581 Approved May 21, 2025.pdf • FOI summary • Official • March 9, 2026
FDA FOI summary for application 141581
FOI Summary sN 141-581 Approved October 20, 2025.pdf • FOI summary • Official • March 9, 2026
FDA FOI summary for application 141581
FOI Summary oN 141-554 Approved July 19, 2023.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141554
FOI Summary sN 141-554 Approved October 7, 2024.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141554
FOI Summary sN 141-554 Approved April 23 2025_EF.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141554
FOI Summary sN 141-554 Approved January 20, 2026.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141554
FOI Summary oN 141-518 Approved November 14, 2019_.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141518
FOI Summary sN 141-518 Approved August 9, 2022.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141518
FOI Summary sN 141-518 Approved January 13, 2026.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 141518
FOI Summary o 141-619 Approved December 17, 2025 (2).pdf • FOI summary • Official • Jan. 5, 2026
FDA FOI summary for application 141619
ANADA 200-700 FOI Summar.pdf • FOI summary • Official • Dec. 16, 2025
FDA FOI summary for application 200700
FOI Summary oA 200-714 Approved November 24, 2021.pdf • FOI summary • Official • Dec. 5, 2025
FDA FOI summary for application 200714
FOI Summary oA 200-818 Approved August 5, 2025.pdf • FOI summary • Official • Aug. 28, 2025
FDA FOI summary for application 200818
FOI Summary oN 141-521 Approved February 27, 2020.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141521
FOI Summary sN 141-521 Approved December 23, 2021.sum.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141521
FOI Summary sN 141-521 Approved November 6, 2024.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141521
FOI Summary sN 141-521 Approved April 8 2025_ceg_ef.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141521
FOI Summary oA 200-718 Approved February 7, 2022.pdf • FOI summary • Official • June 2, 2025
FDA FOI summary for application 200718
FOI Summary oA 200-811 Approved March 24, 2025.pdf • FOI summary • Official • March 28, 2025
FDA FOI summary for application 200811

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 192 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Lack of efficacy (endoparasite) - hookworm, Lethargy (see also Central… (Clinical, 2026-04-11)
contraindications: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral… (Official, 2026-04-12)
contraindications: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral… (Official, 2026-04-11)
contraindications: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral… (Official, 2026-02-12)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-08-06)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-08-05)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-08-04)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-08-03)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-08-02)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-08-01)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-31)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-30)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-29)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-28)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-27)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-26)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-25)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-25)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-22)
indications: CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the f… (Official, 2026-07-22)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Cydectin® OTC Moxidectin Liquid (Solution) • Subcutaneous Label highlights Official documents	Elanco US Inc.	NADA 141-220	Approved	Jun 10, 2026
ProHeart® 12 RX Moxidectin Sterile suspension • Subcutaneous Label highlights Official documents	Zoetis Inc.	NADA 141-519	Approved	May 14, 2026
Moxidectin Oral Drench for Sheep OTC Moxidectin Solution • Oral Label highlights Official documents	First Priority, Inc.	ANADA 200-852	Approved	Apr 30, 2026
MoxiSolv™ Injection OTC Moxidectin Injectable Solution • Subcutaneous Label highlights Official documents	Bimeda Animal Health Ltd.	ANADA 200-788	Approved	Aug 1, 2024
Quest® Gel OTC Moxidectin Gel • Oral Label highlights Official documents	Zoetis Inc.	NADA 141-087	Approved	Sep 19, 2023
Tauramox™ OTC Moxidectin Injectable Solution • Subcutaneous Label highlights Official documents	Norbrook Laboratories, Ltd.	ANADA 200-746	Approved	Apr 3, 2023
Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle OTC Moxidectin Solution • Transdermal Label highlights Official documents	Elanco US Inc.	NADA 141-099	Approved	Jun 8, 2022
ProHeart® 6 RX Moxidectin Microspheres • Subcutaneous Label highlights Official documents	Zoetis Inc.	NADA 141-189	Approved	May 17, 2021
Cydectin® Oral Drench for Sheep OTC Moxidectin Liquid (Solution) • Oral Label highlights Official documents	Elanco US Inc.	NADA 141-247	Approved	Jan 12, 2021
ProHeart™ RX Moxidectin Tablet • Oral Label highlights Official documents	Zoetis Inc.	NADA 141-051	Approved	Jun 18, 2018
CORAXIS™ RX Moxidectin Solution • Topical Label highlights Official documents	Elanco US Inc.	NADA 141-417	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Beef • Dairy

Composition / specifications

Contains 10 mg moxidectin/mL

Cattle (Beef and Non-Lactating Dairy)

Indication

Dosage

0.2 mg/kilogram body weight (0.2 mg/2.2 pound) as a single subcutaneous injection.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: 1 year of age and older

Composition / specifications

Each mL of constituted suspension contains 10 mg moxidectin

Dogs 1 year of age and older

Indication

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

1 mg moxidectin/mL

Sheep

Indication

Dosage

The recommended rate of administration for Moxidectin Oral Drench for Sheep is 1 mL per 11 lb (1 mL per 5 kg) body weight into the mouth of sheep, using any standard drenching equipment.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Beef And Non-Lactating Dairy

Composition / specifications

10 mg moxidectin/mL

Beef and nonlactating dairy cattle

Indication

Lungworms
Dictyocaulus viviparus - Adults and L4

Cattle Grubs
Hypoderma bovis
Hypoderma lineatum

Mites
Psoroptes ovis
(Psoroptes communis var. bovis)

Lice
Linognathus vituli
Solenopotes capillatus

Dosage

1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse • Pony

Composition / specifications

The gel contains 2 percent moxidectin (20 milligrams per milliliter).

Horses and Ponies (6 Months of Age and Older)

Indication

Dosage

0.4 mg moxidectin/ kg body weight

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Beef And Non-Lactating Dairy

Composition / specifications

10 mg moxidectin/mL

Beef and nonlactating dairy cattle

Indication

For the treatment and control of the following internal and external parasites of cattle:

Dosage

Administer by subcutaneous injection 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Beef • Calves • Dairy

Composition / specifications

Each milliliter contains 5 milligrams of moxidectin (0.5 percent solution).

Beef and Dairy Cattle

Indication

Dosage

The recommended rate of administration is 1 mL for each 22 lb (10 kg) of body weight which provides 5 mg moxidectin for each 22 lb (10 kg) of body weight.

Limitations

A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Dogs

Indication

For treatment of existing larval and adult hookworm (Ancylostoma caninum and Unicinaria stenocephala) infections.

Dosage

0.05 mL of the constituted suspension/kg body weight (0.0227 mL/lb). This amount of suspension will provide 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.

Limitations

Indication

For prevention of heartworm disease caused by Dirofilaria immitis.

Dosage

0.05 mL of the constituted suspension/kg body weight (0.0227 mL/lb). This amount of suspension will provide 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Sheep

Composition / specifications

Each milliliter (mL) of solution contains 1 milligram (mg) moxidectin.

Sheep

Indication

Dosage

Administer 1 mL per 11 pounds body weight (1 mL per 5 kilograms) by mouth.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Each tablet contains 30, 68, or 136 micrograms of moxidectin.

Dogs

Indication

To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease.

Dosage

3 micrograms per kilogram (1.36 micrograms per pound) of body weight, once a month.

Limitations

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

2.5% moxidectin

Dogs (Dogs and Puppies At Least 7 Weeks of Age)

Indication

Dosage

Administer topically a minimum of 1.1 mg/lb (2.5 mg/kg) of body weight, once monthly using the appropriate pre-loaded applicator tube.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles : Strongylus vulgaris : (adults and L4 / L5 arterial stages), Strongylus edentatus : (adults and tissue stages), Triodontophorus brevicauda : (adults), Triodontophorus serratus : (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum , Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus , Cylicostephanus goldi , Cylicostephanus longibursatus , Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne , Cylicocyclus leptostomum , Cylicocyclus nassatus , Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus , Coronocyclus labiatus , Coronocyclus labratus , Gyalocephalus capitatus , Petrovinema poculatus Small Strongyles : Undifferentiated lumenal larvae Encysted cyathostomes : Late L3 and L4 mucosal cyathostome larvae Ascarids : Parascaris equorum : (adults and L4 larval stages) Pinworms : Oxyuris equi : (adults and L4 larval stages) Hairworms : Trichostrongylus axei : (adults) Large-mouth stomach worms : Habronema muscae : (adults) Horse stomach bots : Gasterophilus intestinalis : (2nd and 3rd instars), Gasterophilus nasalis : (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older. For treatment and control of internal and external parasites: gastrointestinal roundworms ( Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms ( Dictyocaulus viviparus , adult and L4); cattle grubs ( Hypoderma bovis , H. lineatum ); mites ( Chorioptes bovis , Psoroptes ovis ( P. communis var. bovis )); lice ( Linognathus vituli , Haematopinus eurysternus , Solenopotes capillatus , Bovicola ( Damalinia ) bovis ); and horn flies ( Haematobia irritans ). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Dog Decreased appetite (1) • Dog Bloody diarrhoea (1) • Dog Blood in vomit (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Chewing - pruritus (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic

Unsteady walking (1) • Dog Convulsion (1) • Dog

Showing top 5 for Neurologic.

Behavior

Biting -aggression (1) • Cat Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other

Decreased percentage of reticulocytes (1) • Dog Decreased drinking (1) • Dog Decreased cholesterol (1) • Dog Death by euthanasia (1) • Dog Death (1) • Cat

Show more (18)

Crust (1) • Cat Cough (1) • Dog Corneal opacity (1) • Dog Colitis (1) • Dog Cloudy eye (1) • Dog Chattering of teeth (1) • Dog Bloody stool (1) • Dog Blood in urine (1) • Dog Blistering (1) • Cat Anaphylaxis (1) • Dog Anaemia NOS (1) • Dog Administration error NOS (1) • Dog Abnormal urine odour (1) • Cat Abnormal ultrasound finding (1) • Dog Abnormal stool colouration (1) • Dog Abnormal radiograph finding (1) • Dog Abnormal cytology (1) • Dog Abnormal breathing (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Rottweiler, Male, 8 year, 39.372 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 2.09 mL per animal • Reactions: Lack of efficacy (endoparasite) - heartworm, Weight loss • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014448
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 8.00 Year
Weight: 39.372 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 2.09 mL per animal

Reactions Reported:

Lack of efficacy (endoparasite) - heartworm Weight loss

Outcomes: Ongoing

Dog, ['Terrier - Bull - American Pit', 'Dog (unknown)'], Female, 3 year, 24.494 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1.29 mL per animal • Reactions: Lack of efficacy (endoparasite) - hookworm, Medication error NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014408
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 3.00 Year
Weight: 24.494 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 1.29 mL per animal

Reactions Reported:

Lack of efficacy (endoparasite) - hookworm Medication error NOS

Outcomes: Ongoing

Dog, Retriever - Labrador, Male, 11 year, 38.646 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 2.40 mL per animal • Reactions: Lack of efficacy (endoparasite) - heartworm, Medication error NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014406
Serious AE: Yes
Treated For AE: No
Sex: Male
Age: 11.00 Year
Weight: 38.646 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 2.40 mL per animal

Reactions Reported:

Lack of efficacy (endoparasite) - heartworm Medication error NOS

Outcomes: Ongoing

Dog, ['Retriever - Golden', 'Poodle (unspecified)'], Female, 4 year, 12.61 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.64 mL per animal • Reactions: Lack of efficacy (endoparasite) - tapeworm, Medication error NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014405
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 4.00 Year
Weight: 12.610 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 0.64 mL per animal

Reactions Reported:

Lack of efficacy (endoparasite) - tapeworm Medication error NOS

Outcomes: Ongoing

Dog, ['Shepherd Dog - German', 'Retriever - Labrador'], Female, 5 year, 39.009 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1.80 mL per animal • Reactions: Lack of efficacy (endoparasite) - heartworm, Intentional misuse, Inappropriate schedule of drug administration • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014402
Serious AE: Yes
Treated For AE: No
Sex: Female
Age: 5.00 Year
Weight: 39.009 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 1.80 mL per animal

Reactions Reported:

Lack of efficacy (endoparasite) - heartworm Intentional misuse Inappropriate schedule of drug administration

Outcomes: Ongoing

Dog, Crossbred Canine/dog, Male, 2 year, 25.492 kilogram • Drug: MSK, Suspension, Subcutaneous • Reactions: Lack of efficacy (endoparasite) - hookworm • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014387
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 2.00 Year
Weight: 25.492 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension

Reactions Reported:

Lack of efficacy (endoparasite) - hookworm

Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 11 month, 5.117 kilogram • Drug: MSK, Unknown • Reactions: Suckling disorder NOS, Licking, Skin scab, Peripheral vascular disorder, Pinnal erythema… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014504
Serious AE: No
Treated For AE: Yes
Sex: Male
Age: 11.00 Month
Weight: 5.117 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Suckling disorder NOS Licking Skin scab Peripheral vascular disorder Pinnal erythema Crust Expired drug administered

Outcomes: Outcome Unknown

Dog, Terrier - Yorkshire, Male, 3 year, 6.622 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.33 mL per animal • Reactions: Vomiting, Tiredness (lethargy), Loose bowel • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-014403
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 3.00 Year
Weight: 6.622 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Subcutaneous
Form: Suspension
Dose: 0.33 mL per animal

Reactions Reported:

Vomiting Tiredness (lethargy) Loose bowel

Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Moxidectin

Data freshness

Moxidectin

Medication Snapshot

Moxidectin

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Medications

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

USA-USFDACVM-2026-US-014448

USA-USFDACVM-2026-US-014408

USA-USFDACVM-2026-US-014406

USA-USFDACVM-2026-US-014405

USA-USFDACVM-2026-US-014402

USA-USFDACVM-2026-US-014387

USA-USFDACVM-2026-US-014504

USA-USFDACVM-2026-US-014403

USA-USFDACVM-2026-US-014071

USA-USFDACVM-2026-US-014457

USA-USFDACVM-2026-US-014377

USA-USFDACVM-2026-US-014067

USA-USFDACVM-2026-US-013741

USA-USFDACVM-2026-US-013479

USA-USFDACVM-2026-US-013476

USA-USFDACVM-2026-US-013422

USA-USFDACVM-2026-US-013212

USA-USFDACVM-2026-US-013203

USA-USFDACVM-2026-US-013496

USA-USFDACVM-2026-US-013474

USA-USFDACVM-2026-US-012880

USA-USFDACVM-2026-US-013254

USA-USFDACVM-2026-US-012896

USA-USFDACVM-2026-US-014359

USA-USFDACVM-2026-US-012837

USA-USFDACVM-2026-US-012647

USA-USFDACVM-2026-US-012730

USA-USFDACVM-2026-US-010460

USA-USFDACVM-2026-US-012550

USA-USFDACVM-2025-US-077538

USA-USFDACVM-2025-US-075460

USA-USFDACVM-2025-US-075429

USA-USFDACVM-2025-US-075414

USA-USFDACVM-2025-US-075401

USA-USFDACVM-2025-US-075384

USA-USFDACVM-2025-US-075282

USA-USFDACVM-2025-US-075277

USA-USFDACVM-2025-US-075443

USA-USFDACVM-2025-US-075392

USA-USFDACVM-2025-US-075387

USA-USFDACVM-2025-US-075359

USA-USFDACVM-2025-US-075348

USA-USFDACVM-2025-US-075342

USA-USFDACVM-2025-US-075154

USA-USFDACVM-2025-US-074261

USA-USFDACVM-2025-US-074194

USA-USFDACVM-2025-US-074384

USA-USFDACVM-2025-US-074361

USA-USFDACVM-2025-US-074282